UroGen Pharma shows strong growth with RTGel technology, FDA approvals for JELMYTO and ZUSDURI, and accelerating 2026 revenue outlook. See why URGN stock is a buy.
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for serious diseases, today announced ...
Abeona Therapeutics Inc. (Nasdaq: ABEO), a commercial-stage biopharmaceutical company developing cell and gene therapies for ...
VentureMed Group, Inc., a leading medical device company specializing in vessel preparation and access management ...
Healthcare is changing fast. Automation and tech-driven coding are reshaping the industry’s workforce.Roles are shifting from ...
UroGen Pharma (URGN) announced that the Centers for Medicare and Medicaid Services, CMS, has assigned a permanent Healthcare Common Procedure ...
UroGen Pharma Ltd. (Nasdaq: URGN), a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that the Centers for ...
Revenue growth for the September 2025 quarter compared with the June 2025 quarter was driven by a 66% increase in Ryoncil® gross sales to US$21.9 million and 69% increase in net sales to US$19.1 ...
Mesoblast Limited (NASDAQ:MESO) is one of the best hot stocks to invest in. On October 3, Mesoblast Limited announced that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback